Álvaro Rodríguez-Lescure

Head

University Hospital Erlangen

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Cancer Biology Cancer Biology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Álvaro Rodríguez-Lescure is the Head at Hospital General Universitario de Elche in Spain. His research areas include oncology, with a focus on tumor boards, treatment strategies for metastatic triple-negative breast cancer, and the efficacy of adjuvant therapies in early-stage breast cancer patients. He has contributed significantly to the field through various recent publications addressing clinical leadership in tumor boards, resource management in oncology, and treatment outcomes for breast cancer patients.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (1)

Sara Lopez-Tarruella

ASSOCIATE PROFESSOR

Universidad Complutense de Madrid

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Álvaro Rodríguez-Lescure

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

Reply to: From Discussion to Direction: Tumor Boards Need Clinical Editorial Leadership

Addressing Tumor Board Bad Habits and Risks: A Call for Rational Resource Management

Reply to: Correction Regarding Commentary “Comprehensive Cancer Infrastructures for the European Union—Coordination and Support Action—CCI4EU CSA”

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

Correction to: Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence (Targeted Oncology, (2025), 10.1007/s11523-024-01125-1)

Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study

Potential Negative Impacts of the CCI4EU Initiative on Spain

Collaborators (1)

Sara Lopez-Tarruella

Make your next move.